ANT-GROUP
30.5.2022 07:41:08 CEST | Business Wire | Press release
Marriott International has signed a partnership agreement with Ant Group to enhance its digital operations in the Chinese market by providing Alipay members with various benefits when they sign up for the Marriott Bonvoy Rewards Program, Marriott’s signature loyalty program. Marriott International will deliver more membership benefits with upgrades on products and services to further improve the consumer experience under its strong brand portfolio.
The partnership with Alipay, the leading digital open platform under Ant Group, will further expand the potential for Marriott International to serve more customers in China. This is in addition to the more than 10 million newly-enrolled members the company has gained through various channels since 2017, including its official flagship storefront in partnership with Fliggy, as well as various consumer partnerships with Alibaba Group and Ant Group. The partnership also presents more opportunities for the tourism industry to embrace digital transformation in its operations.
“Marriott International has a long history in China, and with more than 450 operating hotels across 23 brands in Greater China, we are committed to catering to the needs and preferences of all our guests,” said Mr. Henry Lee, President, Greater China, Marriott International. “Our diverse brand portfolio offers further opportunities for innovative collaborations with Ant Group. To support the recovery of the travel industry, we are looking to offer exclusive travel experiences for high-net-worth members using Alipay.”
“We are delighted to extend our partnership with Marriott International, to enhance its digital operations and provide Alipay users with improved benefits,” said Kelly Li, General Manager overseeing user operations at Alipay and Vice President of Ant Group. “Marriott International operates with a strong brand portfolio and connects us with a diverse range of clients with its award-winning Marriott Bonvoy Rewards Program. Following this partnership, we look forward to working with more partners and providing more comprehensive and exclusive experiences to Alipay users.”
“We studied what Chinese consumers want, and partnered with Ant Group to provide a new way of enjoying our Marriott Bonvoy loyalty program,” said Ms. Julie Purser, Vice President, Marketing, Loyalty & Partnerships, Asia Pacific, Marriott International. “With this development, we hope to keep up with digital marketing trends in China. We are excited to offer travelers more ways to follow their passion and experience unforgettable journeys.”
From May 24, 2022 to March 31, 2023, qualified Alipay members can sign up for a Marriott Bonvoy membership through the app and enjoy different levels of benefits. They can collect a special digital coupon (worth 30 RMB) for afternoon tea at Marriott International hotels and join a lucky draw to enjoy afternoon tea by spending 1 RMB at Marriott International.
From May 24, 2022 to June 24, 2022, new members can enjoy breakfast by spending only 1 RMB at selected Marriott International hotels in various cities, including Guangzhou, Shenzhen, Hangzhou, Chengdu and Sanya. Through Marriott International’s company-wide ‘Commitment to Clean’ policy, the company is committed to meeting local hygiene and safety guidelines to ensure the health and safety of all guests.
Looking ahead, Marriott International will continue to deepen its partnership with Alibaba Group and Ant Group to bring more inspirations for travelers with exclusive membership benefits.
About Marriott International
Marriott International, Inc. (NASDAQ: MAR) is based in Bethesda, Maryland, USA, and encompasses a portfolio of more than 8,000 properties under 30 leading brands spanning 139 countries and territories. Marriott operates and franchises hotels and licenses vacation ownership resorts all around the world. The company offers Marriott Bonvoy®, its highly-awarded travel program. For more information, please visit our website at www.marriott.com , and for the latest company news, visit www.marriottnewscenter.com . In addition, connect with us on Facebook and @MarriottIntl on Twitter and Instagram .
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable. For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom